GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sci Pharmtech Inc (TPE:4119) » Definitions » EV-to-FCF

Sci Pharmtech (TPE:4119) EV-to-FCF : -112.11 (As of Apr. 05, 2025)


View and export this data going back to 2004. Start your Free Trial

What is Sci Pharmtech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sci Pharmtech's Enterprise Value is NT$9,655 Mil. Sci Pharmtech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-86 Mil. Therefore, Sci Pharmtech's EV-to-FCF for today is -112.11.

The historical rank and industry rank for Sci Pharmtech's EV-to-FCF or its related term are showing as below:

TPE:4119' s EV-to-FCF Range Over the Past 10 Years
Min: -129.49   Med: 12.2   Max: 2499.7
Current: -115.86

During the past 13 years, the highest EV-to-FCF of Sci Pharmtech was 2499.70. The lowest was -129.49. And the median was 12.20.

TPE:4119's EV-to-FCF is ranked worse than
100% of 548 companies
in the Drug Manufacturers industry
Industry Median: 23.575 vs TPE:4119: -115.86

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-05), Sci Pharmtech's stock price is NT$78.30. Sci Pharmtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was NT$4.460. Therefore, Sci Pharmtech's PE Ratio (TTM) for today is 17.56.


Sci Pharmtech EV-to-FCF Historical Data

The historical data trend for Sci Pharmtech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sci Pharmtech EV-to-FCF Chart

Sci Pharmtech Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.02 -14.80 -11.00 -14.23 -129.18

Sci Pharmtech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -14.23 -27.52 -13.93 -16.20 -129.18

Competitive Comparison of Sci Pharmtech's EV-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Sci Pharmtech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sci Pharmtech's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sci Pharmtech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Sci Pharmtech's EV-to-FCF falls into.


;
;

Sci Pharmtech EV-to-FCF Calculation

Sci Pharmtech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=9655.157/-86.122
=-112.11

Sci Pharmtech's current Enterprise Value is NT$9,655 Mil.
Sci Pharmtech's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sci Pharmtech  (TPE:4119) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Sci Pharmtech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=78.30/4.460
=17.56

Sci Pharmtech's share price for today is NT$78.30.
Sci Pharmtech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.460.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Sci Pharmtech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Sci Pharmtech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Sci Pharmtech Business Description

Traded in Other Exchanges
N/A
Address
No.61, Lane 309, Haihu North Road, Luzhu District, Taoyuan, TWN, 33856
Sci Pharmtech Inc is engaged in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. Geographically, the primary markets of the company are Italy, Germany, Japan, Taiwan, the United States, China, Switzerland, Spain, and others.

Sci Pharmtech Headlines

No Headlines